Human Health
Research and Development of a Novel Treatment for Hypertrophic Scarring and Keloids
ViDa- Project Leaders: Alistair Duncan, Beth Allison, Taryn Boivin
- Institutions: viDA Therapeutics Inc
- Budget: $1009943
- Program/Competition: Strategic Opportunities Fund for Industry
- Genome Centre(s): Genome British Columbia
- Status: Closed
Hypertrophic scar formation arising from burn injuries, traumatic injuries, and surgical procedures is a major clinical problem in the developing and industrialized worlds. The cost of treatment is estimated to be $4B annually in the US alone and there is no cost effective, broadly efficacious, commercial treatment available.
This project at viDA Therapeutics supported pre-clinical development of V2248, a small molecule drug treatment of hypertrophic scarring and keloids. The project validated a model of hypertrophic scarring that can be used to test the efficacy of new therapies.
